rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Andrew J. Schwab

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Skye Bioscience; Director and 10% owner, CAMP4 Therapeutics; 10% owner, Entrada Therapeutics; Director and 10% owner, Enliven Therapeutics; 10% owner, Rallybio; 10% owner, CinCor Pharma; 10% owner, Akouos; Director and 10% owner, Pear Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
153
Buys
4
Sells
30
Bought
$25.0M
Sold
$62.6M
Companies
16
Companies where not an officer
15
First trade
18 Feb 2014
Last trade
23 Sep 2026
Last filed
24 Sep 2026

Companies traded

Where they are an officer
5:01 AcquisitionDirector, Officer, 10% owner · last 30 Nov 20200 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
SKYE Skye BioscienceDirector, 10% owner · Biotechnology · last 23 Sep 20260 buys · 10 sells
CAMP CAMP4 TherapeuticsDirector, 10% owner · Biotechnology · last 27 Aug 20261 buy · 5 sells
TRDA Entrada Therapeutics10% owner · Biotechnology · last 1 Jul 20251 buy · 3 sells
ELVN Enliven TherapeuticsDirector, 10% owner · Biotechnology · last 24 Aug 20230 buys · 1 sell
RLYB Rallybio10% owner · Biotechnology · last 7 Mar 20230 buys · 1 sell
CinCor Pharma10% owner · last 24 Feb 20230 buys · 0 sells
Akouos10% owner · last 30 Nov 20220 buys · 0 sells
Pear TherapeuticsDirector, 10% owner · last 18 Aug 20220 buys · 3 sells
VOR Vor Biopharma10% owner · Biotechnology · last 16 Nov 20210 buys · 1 sell
FIXX Leverage Shares 2X Long FIX Daily ETF10% owner · last 14 Dec 20200 buys · 2 sells
CABA Cabaletta Bio10% owner · Biotechnology · last 10 Dec 20201 buy · 1 sell
IDYA IDEAYA Biosciences10% owner · Biotechnology · last 11 Nov 20200 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
80Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$185K114,851 at $1.61filing
23 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$7,2904,528 at $1.61filing
23 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$185K114,851 at $1.61filing
23 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$7,2904,528 at $1.61filing
22 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$46K27,612 at $1.65filing
22 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$1,7951,088 at $1.65filing
22 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$46K27,612 at $1.65filing
22 Sep 2026filed 24 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$1,7951,088 at $1.65filing
16 Sep 2026filed 18 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$62K32,607 at $1.91filing
16 Sep 2026filed 18 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$2,4541,285 at $1.91filing
16 Sep 2026filed 18 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$62K32,607 at $1.91filing
16 Sep 2026filed 18 Sep 2026SKYE Skye BioscienceBiotechnologySEC FORM 4 Sold$2,4541,285 at $1.91filing
27 Aug 2026filed 31 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$1.6M400,000 at $4.04filing
27 Aug 2026filed 31 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$1.6M400,000 at $4.04filing
24 Aug 2026filed 26 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$4510 at $4.50filing
24 Aug 2026filed 26 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$4510 at $4.50filing
21 Aug 2026filed 21 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$144K32,018 at $4.50filing
21 Aug 2026filed 21 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$144K32,018 at $4.50filing
20 Aug 2026filed 21 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$521K114,700 at $4.54filing
20 Aug 2026filed 21 Aug 2026CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Sold$521K114,700 at $4.54filing

News

Critical Analysis: Iovance Biotherapeutics (NASDAQ:IOVA) vs. CAMP4 Therapeutics (NASDAQ:CAMP)CAMP · tickerreport.com · 24 Oct 2026

0 headlines in the last 90 days name Andrew J. Schwab; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care28
Not placed6

Buys in green, sells in red, by the company’s sector.

Related people

Benjamin HohlChief Financial Officer · Also traded ELVN in the last 90 days
Helen Louise CollinsChief Medical Officer · Also traded ELVN in the last 90 days
Yujiro S. HataPresident and CEO · Also traded IDYA in the last 90 days
J. Scott GarlandDirector · Also traded ELVN in the last 90 days
5AM Partners VII, LLC10% owner · Also traded SKYE in the last 90 days
MPM BioVentures 2014, L.P.10% owner · Also traded TRDA in the last 90 days
MPM BIOVENTURES 2018, L.P.10% owner · Also traded TRDA in the last 90 days
Kelly GoldChief Financial Officer · Also traded CAMP in the last 90 days